Market Cap 302.20M
Revenue (ttm) 36.33M
Net Income (ttm) -85.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -234.38%
Debt to Equity Ratio -2.40
Volume 10,898,600
Avg Vol 1,751,720
Day's Range N/A - N/A
Shares Out 53.30M
Stochastic %K 63%
Beta 0.31
Analysts Sell
Price Target $11.84

Company Profile

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 517 0730
Address:
25 Mall Road, Suite 203, Burlington, United States
BeefStewart
BeefStewart May. 5 at 4:53 PM
$RCEL I feel really bullish about this, but I understand that the stock price has been languishing over time. One thing I notice is the low trading liquidity. It reminds me of $SCPH last year. Anyone have any insights into earnings expectations?
0 · Reply
BeefStewart
BeefStewart May. 4 at 2:54 PM
$ADMA I remember in March of 2025 when $SCPH received a favorable FDA decision, leading to the stock selling off... It would eventually go up, but selling the news is a real thing sometimes...
1 · Reply
MITornado
MITornado Apr. 30 at 7:44 PM
$SCPH what’s the date for the auto injector approval?
0 · Reply
clan
clan Apr. 28 at 9:09 AM
$MNKD $SCPH $BX Furoscix / SCPharma Div. is expected to be accretive to Mannkind's earnings by 3Q26. Low-COGS Readyflow autoinjector. FDA approval. Hours to seconds. Thank you Blackstone for your attention to this matter. $IBB
0 · Reply
clan
clan Apr. 23 at 12:05 PM
$MNKD Care transformation = huge Revenues $SCPH $BX $SPY
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 16 at 12:40 AM
The attachment compares $ZVRA valuation, analyst consensus & related multiples to the same from 11 peer commercial-stage biopharma M&A transactions. Analysts forecast ZVRA to generate $1.438B in revenues over the next 5 years (FY26 - 30). This is, more or less, consistent with the 5 year revenue forecasts prepared by the mgmt/BOD of $SCPH BDSI & RDUS when they were acquired for enterprise values of $300 to $840MM. ZVRA has $176MM net cash/debt at 12/31/25 so their enterprise value is ~$430MM (versus the $606MM noted as market cap used to calculate multiples). We're curious which, if any, peer of the 11 on the attachment that exited via M&A is a good comp for ZVRA. Other bios with similar forecasts include $CRMD $HRTX & $AQST We're only sharing our analysis. This is not investment advice.
1 · Reply
grampslol
grampslol Mar. 14 at 8:41 AM
$MNKD poor @clan....smh...deluding himself as he tries to chump others...a sad fellow $SCPH $UTHR #afizzle
0 · Reply
clan
clan Mar. 14 at 8:34 AM
$MNKD $UTHR $SCPH The Fix Is In!
0 · Reply
OldManLogan
OldManLogan Mar. 12 at 2:02 PM
$ESPR Honestly, you know what I'm fed up with? Posts like this, and there are a lot of them lately. Most come from fake bulls, but for those that are actually invested in ESPR, give your head a shake. WTF were people's expectations when they first invested? Less than 10% of biotechs with a market cap under $1B are profitable and yet people still consistently invest in them. Why? Bios trade based on future expectations; otherwise no one would ever buy pre or early commercial bios. ESPR has the potential to be a 10X return from here; those types of returns don't come without risk. Unlike the majority of bios that will never be profitable; ESPR is clearly on the cusp of positive cash flow then positive earnings. If you don't believe that, get out. But don't pretend that this isn't the playbook for sooo many early commercial bios. I have found that to be the sweet spot between risk and reward and done well with names like $ADMA $TGTX and $SCPH. ESPR will be the same.
2 · Reply
clan
clan Feb. 26 at 6:15 PM
$MNKD $SPY @MrMulally @MayorofMNKD APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $3 -- acquisition of scPharma [ $SCPH ] + $2 -- label change - Afrezza + $8 -- pediatric Afrezza + $5 -- FDA approval of Furoscix auto injector + $2 -- gestational Afrezza + $5 -- 2nd Unither collaboration [ $UTHR ] + $6 -- Clofazimine DPI [MNKD-102] + $9 -- Nintedanib DPI [MNKD-201] -------- +$40/sh
1 · Reply
Latest News on SCPH
BeefStewart
BeefStewart May. 5 at 4:53 PM
$RCEL I feel really bullish about this, but I understand that the stock price has been languishing over time. One thing I notice is the low trading liquidity. It reminds me of $SCPH last year. Anyone have any insights into earnings expectations?
0 · Reply
BeefStewart
BeefStewart May. 4 at 2:54 PM
$ADMA I remember in March of 2025 when $SCPH received a favorable FDA decision, leading to the stock selling off... It would eventually go up, but selling the news is a real thing sometimes...
1 · Reply
MITornado
MITornado Apr. 30 at 7:44 PM
$SCPH what’s the date for the auto injector approval?
0 · Reply
clan
clan Apr. 28 at 9:09 AM
$MNKD $SCPH $BX Furoscix / SCPharma Div. is expected to be accretive to Mannkind's earnings by 3Q26. Low-COGS Readyflow autoinjector. FDA approval. Hours to seconds. Thank you Blackstone for your attention to this matter. $IBB
0 · Reply
clan
clan Apr. 23 at 12:05 PM
$MNKD Care transformation = huge Revenues $SCPH $BX $SPY
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 16 at 12:40 AM
The attachment compares $ZVRA valuation, analyst consensus & related multiples to the same from 11 peer commercial-stage biopharma M&A transactions. Analysts forecast ZVRA to generate $1.438B in revenues over the next 5 years (FY26 - 30). This is, more or less, consistent with the 5 year revenue forecasts prepared by the mgmt/BOD of $SCPH BDSI & RDUS when they were acquired for enterprise values of $300 to $840MM. ZVRA has $176MM net cash/debt at 12/31/25 so their enterprise value is ~$430MM (versus the $606MM noted as market cap used to calculate multiples). We're curious which, if any, peer of the 11 on the attachment that exited via M&A is a good comp for ZVRA. Other bios with similar forecasts include $CRMD $HRTX & $AQST We're only sharing our analysis. This is not investment advice.
1 · Reply
grampslol
grampslol Mar. 14 at 8:41 AM
$MNKD poor @clan....smh...deluding himself as he tries to chump others...a sad fellow $SCPH $UTHR #afizzle
0 · Reply
clan
clan Mar. 14 at 8:34 AM
$MNKD $UTHR $SCPH The Fix Is In!
0 · Reply
OldManLogan
OldManLogan Mar. 12 at 2:02 PM
$ESPR Honestly, you know what I'm fed up with? Posts like this, and there are a lot of them lately. Most come from fake bulls, but for those that are actually invested in ESPR, give your head a shake. WTF were people's expectations when they first invested? Less than 10% of biotechs with a market cap under $1B are profitable and yet people still consistently invest in them. Why? Bios trade based on future expectations; otherwise no one would ever buy pre or early commercial bios. ESPR has the potential to be a 10X return from here; those types of returns don't come without risk. Unlike the majority of bios that will never be profitable; ESPR is clearly on the cusp of positive cash flow then positive earnings. If you don't believe that, get out. But don't pretend that this isn't the playbook for sooo many early commercial bios. I have found that to be the sweet spot between risk and reward and done well with names like $ADMA $TGTX and $SCPH. ESPR will be the same.
2 · Reply
clan
clan Feb. 26 at 6:15 PM
$MNKD $SPY @MrMulally @MayorofMNKD APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $3 -- acquisition of scPharma [ $SCPH ] + $2 -- label change - Afrezza + $8 -- pediatric Afrezza + $5 -- FDA approval of Furoscix auto injector + $2 -- gestational Afrezza + $5 -- 2nd Unither collaboration [ $UTHR ] + $6 -- Clofazimine DPI [MNKD-102] + $9 -- Nintedanib DPI [MNKD-201] -------- +$40/sh
1 · Reply
clan
clan Feb. 23 at 5:14 PM
$MNKD Busy little beaver, Binder, making advancements behind the scenes... for the good of all Mannkind! $UTHR $SCPH $BX
0 · Reply
clan
clan Feb. 8 at 4:32 PM
$MNKD APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [Before EOY 2028]: + $3 -- acquisition of scPharma [ $SCPH ] + $2 -- label change - Afrezza + $7 -- pediatric Afrezza + $5 -- FDA approval of Furoscix auto injector + $2 -- gestational Afrezza + $6 -- 2nd Unither DPI drug [ $UTHR ] + $6 -- Clofazimine DPI [MNKD-102] + $9 -- Nintedanib DPI [MNKD-201] + $3 -- TYVASO for IPF + $6 -- TYVASO for PPF -------- +$49/sh. 🐂
1 · Reply
clan
clan Feb. 8 at 1:12 AM
$MNKD Over $10,000,000,000 / yr! That's Billion with a "B" .... per year. $SCPH #HighMarginAutoInjector $MRK $AMGN
0 · Reply
ZacksResearch
ZacksResearch Jan. 19 at 1:40 PM
$MNKD up 36.4% in six months — and the news flow is stacking 📈 FDA accepted Afrezza®’s sBLA for pediatric diabetes (PDUFA May 29, 2026), potentially the first needle-free insulin option for kids in 100+ years. FUROSCIX ReadyFlow Autoinjector also got FDA review with a July 26, 2026 PDUFA, delivering an IV-equivalent dose in under 10 seconds ⚡ Add in MNKD-201 advancing in clinical trials and the $360M acquisition of $SCPH bringing FDA-approved FUROSCIX and a $10B+ U.S. TAM — momentum is real. Latest MNKD news here 👉 https://www.zacks.com/stock/quote/MNKD?q=MNKD&cid=sm-stocktwits-0-quote_overview-oc-29433&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_29433
0 · Reply
clan
clan Jan. 11 at 2:20 AM
$MNKD 2026 for Mannkind Corp. and MNKD will be transfomational; an inflection point. #ItsGrowTime #StockAppreciation $UTHR $SCPH
0 · Reply
hanovk68
hanovk68 Jan. 5 at 10:25 PM
$SCPH do we have any idea about furoscix sales and whether former SCPH shareholders will get their buyout bump in March?
1 · Reply
clan
clan Dec. 29 at 2:52 PM
$MNKD = $50/sh by end of 2028. ​MNKD = $26/sh in '26. APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $3 -- acquisition of scPharma [ $SCPH ] ('25) + $5 -- FDA approval of Furoscix auto injector ('26) + $7 -- pediatric Afrezza ('26) + $3 -- gestational Afrezza ('26) + $6 -- 2nd Unither DPI drug [ $UTHR ] + $6 -- Clofazimine DPI [MNKD-102] ('28) + $9 -- Nintedanib DPI [MNKD-201] ('28) + $3 -- TYVASO for IPF ('27) + $6 -- TYVASO for PPF ('28) -------- +$48/sh 🐂
2 · Reply
clan
clan Dec. 27 at 1:08 PM
$MNKD $SCPH $UTHR $BX Continuing the progress from 2025, Mannkind's 2026 is set up for 4 subsequent quarters of RECORD Revenues; one right after the next ...
0 · Reply
clan
clan Dec. 23 at 5:27 PM
$MNKD $SCPH $BX Good news [ for all of Mannkind ] keeps rolling in! More is incoming... 🐂
0 · Reply
clan
clan Dec. 21 at 10:32 PM
$MNKD @neil36 @Harryx1 @MayorofMNKD @MrMulally There's 10 days left in this Mannkind's highest Revenue-generating quarter ever. Est. ~$110M ! If the consolidated bottom line remains positive for the qrt., that'll be a bonus. $SCPH scPharma (Furoscix) division w/b accretive to EPS in 3Q26; maybe even 2Q26. Looking frwd to all the updates during FY25 Earnings release at end of Feb. [~2/26/26]. (A published financial outlook in advance by mgmt w/b nice). 🐂
0 · Reply
clan
clan Dec. 12 at 11:12 AM
$MNKD $SCPH $BX It's coming. #ThenComesAutoInjector
0 · Reply
clan
clan Dec. 5 at 9:28 AM
$MNKD is up 29% over the recent 6 months for a multitude and combination of reasons. To certainly go higher as time moves forward. Onward and upward. ↗️ In part due to $UTHR $SCPH and $BX #afrezza #inhalemyinsulin
0 · Reply